Allarity Therapeutics, Inc. (ALLR): Termination of a Material Definitive Agreement
Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. Termination of Common Stock Purchase Agreement On October 28, 2026, Allarity Therapeutics, Inc. (the “Company”) terminated the Common Stock Purchase Agreement, dated January 28, 2026 (the “Purchase Agreement”), by and betw
- Instrument
- Common Stock Purchase Agreement
- Gross proceeds
- up to $6.0 million
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The filing signals a shift in capital‑raising strategy, which could affect short‑term liquidity and share price.
Market read
Primary disclosure of a material corporate action for a micro‑cap biotech; modest trading relevance.
What to watch
Potential upcoming private placement or debt financing not disclosed in the filing.
Background
Allarity Therapeutics is a clinical‑stage biotech that previously secured a $6 M equity purchase agreement to fund its pipeline.
Ticker impact
Allarity Therapeutics filed an 8‑K announcing termination of its $6 million Common Stock Purchase Agreement with Tumim Stone Capital.
likely pressure as the market prices in the loss of up‑to‑$6 M of equity financing
No alternative financing disclosed; investors may view the move as a setback to capital raising plans.
Market effects
Minimal; limited to biotech financing dynamics.
None beyond the company.
Low; micro‑cap event.
Counterpoint
The termination may free the company from restrictive terms and allow a more favorable financing route.
Key entities
- companyAllarity Therapeutics, Inc.
Biotech issuer of the terminated agreement.
- investorTumim Stone Capital LLC
Counterparty to the terminated purchase agreement.
